Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Ligand Pharmaceuticals Inc.    LGND   US53220K5048

SummaryQuotesChart AnalysisNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Ligand Pharmaceuticals Inc. : SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Possible Breaches of Fiduciary Duty by the Board of Directors of Ligand Pharmaceuticals Incorporated

05/17/2013 | 12:55pm US/Eastern

NEW YORK, May 17, 2013 /PRNewswire/ -- Levi & Korsinsky, LLP is investigating Ligand Pharmaceuticals Incorporated (NasdaqGM: LGND), and its Board of Directors, in connection with possible claims of breaches of fiduciary duty.


To get more information, click here: There is no cost or obligation to you.

If you own common stock in Ligand Pharmaceuticals Incorporated and wish to obtain additional information, please contact Eduard Korsinsky, Esq. either via email at or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit

Levi & Korsinsky is a national firm with offices in New York, New Jersey, and Washington D.C. The firm has extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. The attorneys at Levi & Korsinsky have been appointed by numerous courts throughout the country to serve as lead counsel on behalf of shareholders in major securities lawsuits and have successfully recovered multimillion-dollar damages awards on behalf of investors. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.

Levi & Korsinsky, LLP
Eduard Korsinsky, Esq.
30 Broad Street - 24th Floor
New York, NY 10004
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171

SOURCE Levi & Korsinsky, LLP

React to this article
01:28a LIGAND PHARMACEUTICALS : Schedules Release of Fourth Quarter Results
01/28 LIGAND PHARMACEUTICALS : to Present at BIO CEO and RBC Capital Markets Global He..
01/27 LIGAND PHARMACEUTICALS : to Report Fourth Quarter Results on February 9th
01/23 LIGAND PHARMACEUTICALS : Partner Retrophin Receives Orphan Drug Designation for ..
01/18 LIGAND PHARMACEUTICALS : Partner Retrophin Gets Orphan Drug Designation for Spar..
01/18 LIGAND PHARMACEUTICALS : Retrophin Gets FDA Designation for Sparsentan
01/14 LIGAND PHARMACEUTICALS : Partner Melinta Therapeutics Reports Positive Phase 3 R..
01/14 LIGAND PHARMACEUTICALS : Partner Retrophin Secures Orphan Drug Designation for S..
01/14 LIGAND PHARMACEUTICALS : Retrophin Receives FDA Designation for Sparsentan
01/13 LIGAND PHARMACEUTICALS : Partner Melinta Therapeutics Highlights Positive Phase ..
Dynamic quotes